MTOR and cancer: A study investigated the somatic alterations involving the PI3K/AKT/mTOR pathway in pan-cancers, finding mutations or copy number alterations in PIK3CA (14% mutated, 6% amplified), PTEN (9% mutated, 7% deletion or two-hit loss), PIK3R1 (4% mutated), AKT1 (1% mutated, 3% amplified), and MTOR (4% amplified) [24].